Identifying successful biomarkers for patients with non-small-cell lung cancer

Alex Friedlaender, Joshua Bauml, Giuseppe Luigi Banna, Alfredo Addeo, Alex Friedlaender, Joshua Bauml, Giuseppe Luigi Banna, Alfredo Addeo

No abstract available

Keywords: NSCLC; TMB; biomarker.

Conflict of interest statement

Financial & competing interests disclosure A Friedlaender has received compensation from Roche, Pfizer, Astellas and BMS for advisory roles. JM Bauml reported receiving research funding to his institution from Merck & Co, Incyte Corp, Carevive Systems, Novartis International AG, Bayer, Janssen Pharmaceutica, AstraZeneca, Takeda Pharmaceutical Company Ltd and Amgen, Inc.; performing consultative services for Bristol-Myers Squibb, AstraZeneca, Celgene Corporation, Merck & Co, Janssen Pharmaceutica, Genentech, Inc., Guardant Health, Inc., Boehringer Ingelheim, Takeda Pharmaceutical Company Ltd, Ayala and Regeneron Pharmaceuticals, Inc. A Addeo has received compensation from Takeda, MSD, BMJ, AstraZeneca, Roche and Pfizer for service on advisory boards. A Addeo also declares research grant from Boehringer to the Bristol University Hospital Trust (previous employment). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
    1. Lemjabbar-Alaoui H, Hassan OU, Yang Y-W, Buchanan P. Lung cancer: biology and treatment options. Biochim. Biophys. Acta. 1856(2), 189–210 (2015).
    1. Garon EB, Hellmann MD, Costa EC. et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: results from KEYNOTE-001. Presented at: ASCO Annual Meeting. IL, USA, 31 May–4 June 2019.
    1. Novello S, Milella M, Tiseo M. et al. Maintenance therapy in NSCLC: why? To whom? Which agent? J. Exp. Clin. Cancer Res. 30(1), 50 (2011).
    1. Pabani A, Butts CA. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer. Curr. Oncol. 25(Suppl. 1), S94–S102 (2018).
    1. Addeo A, Banna GL, Metro G, Di Maio M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front. Oncol. 9, 264 (2019).
    1. Reck M, Rodríguez-Abreu D, Robinson AG. et al. KEYNOTE-024: pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Ann. Oncol. 27(Suppl. 6), LBA8_PR (2016).
    1. Tsao MS, Kerr KM, Kockx M. et al. PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint Phase II project. J. Thorac. Oncol. 13(9), 1302–1311 (2018).
    1. Mazieres J, Drilon A, Lusque A. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30(8), 1321–1328 (2019).
    1. Lee HH, Wang YN, Xia W. et al. Removal of N-Linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell 36(2), 168–178.e164 (2019).
    1. Mclaughlin J, Han G, Schalper KA. et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2(1), 46–54 (2016).
    1. Hellmann MD, Ciuleanu TE, Pluzanski A. et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378(22), 2093–2104 (2018).
    1. Addeo A, Banna GL, Weiss GJ. Tumor mutation burden – from hopes to doubts. JAMA Oncol. 5(7), 934–935 (2019).
    1. Rizvi NA, Hellmann MD, Snyder A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
    1. Banna GL, Olivier T, Rundo F. et al. The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front. Med. 6, 172 (2019).
    1. Lee JS, Ruppin E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. (2019) (Epub ahead of print).
    1. Bange E, Marmarelis ME, Hwang W-T. et al. Impact of KRAS and TP53 Co-mutations on outcomes after first-line systemic therapy among patients with STK11-mutated advanced non-small-cell lung cancer. JCO Precis. Oncol. 3, (2019) (Epub ahead of print).
    1. de Lima VCC, de Sa VK, Chinoca JP. et al. Frequency and prognostic impact of concomitant mutations in KRAS and TP53 or STK11 in Brazilian lung adenocarcinoma patients. Presented at: The IASLC World Conference on Lung Cancer. Barcelona, Spain, 7–10 September 2019.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren